The purpose of this research is to determine the safety and efficacy of withdrawing MMF (Mycophenolate Mofetil) in kidney transplant recipients who are 55 years or older at the time of receiving a kidney transplant. We are comparing them to patients who receive the standard of care Mycophenolate Mofetil.

Start Date02 Jan 2025

Sponsor / Collaborator

Mayo Clinic

[+2]

NCT05326087 / Not yet recruitingPhase 3IIT

A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the PPOS (Progestin-primed Ovarian Stimulation) Protocol and the Gonadotropin-releasing Hormone (GnRH) Antagonist Protocol in Women With PCOS (Polycystic Ovary Syndrome) Undergoing PGT-A (Preimplantation Genetic Testing for Aneuploidy)

This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:
Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger.
The primary outcome is the euploidy rate of blastocysts.

Start Date01 Dec 2024

Sponsor / Collaborator

ShangHai Ji Ai Genetics & IVF Institute

NCT06478017 / RecruitingPhase 2IIT

Belatacept With Delayed Tacrolimus Withdrawal Versus Standard-of-Care Tacrolimus in Heart Transplant Recipients (RTB-013)

This is a phase 2, prospective, multi-center, open-label clinical trial. Sixty-six (66) primary heart transplant recipients will be randomized (1:2) to receive either standard-of-care, tacrolimus-based immunosuppression, or a belatacept-based regimen with gradual tacrolimus withdrawal over 9-months post-transplant. Both study arms will receive CellCept® (mycophenolate mofetil- MMF) or Myfortic® (mycophenolate sodium). Corticosteroids will be continued throughout the study in the belatacept arm.
The primary objective is to evaluate whether NULOJIX® (belatacept), when implemented with gradual tacrolimus withdrawal over 9 months, is safe with respect to preventing the composite endpoint of acute cellular rejection (ACR) >= International Society of Heart and Lung Transplantation (ISHLT) 2R, hemodynamic compromise rejection in the absence of a biopsy or histological rejection, re-transplantation, and death at 18 months post-transplant.

Start Date18 Nov 2024

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with Mycophenolate Mofetil

100 Translational Medicine associated with Mycophenolate Mofetil

100 Patents (Medical) associated with Mycophenolate Mofetil

15,709

Literatures (Medical) associated with Mycophenolate Mofetil

01 Jan 2025·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Attenuated neutralization, maintained specificity: Humoral response to SARS-CoV-2 booster in kidney allograft recipients

Article

Author: Hruby, Filip ; Petr, Vojtech ; Cecrdlova, Eva ; Zahradka, Ivan ; Modos, Istvan ; Striz, Ilja ; Viklicky, Ondrej ; Fialova, Martina

Despite the lower virulence of current SARS-CoV-2 variants and high rates of vaccinated and previously infected subjects, COVID-19 remains a persistent threat in kidney transplant recipients (KTRs). This study evaluated the parameters of anti-SARS-CoV-2 antibody production in 120 KTRs. The production of neutralizing antibodies in KTRs, following booster vaccination with the mRNA vaccine BNT162b2, was significantly decreased and their decline was faster than in healthy subjects. Factors predisposing to the downregulation of anti-SARS-CoV-2 neutralizing antibodies included age, lower estimated glomerular filtration rate, and a full dose of mycophenolate mofetil. Neutralizing antibodies correlated with those targeting the SARS-CoV-2 receptor binding domain (RBD), SARS-CoV-2 Spike trimmer, total SARS-CoV-2 S1 protein, as well as with antibodies to the deadly SARS-CoV-1 virus. No cross-reactivity was found with antibodies against seasonal coronaviruses. KTRs exhibited lower postvaccination production of neutralizing antibodies against SARS-CoV-2; however, the specificity of their humoral response did not differ compared to healthy subjects.

31 Dec 2024·Virulence

Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition of nucleic acid synthesis, mRNA splicing, and protein stability

Article

Author: Pu, Feiyang ; Wang, Xin ; Feng, Xili ; Yang, Xuanye ; Duan, Kai ; Ma, Zhongren ; Yang, Xiao-Ming ; Nian, Xuanxuan ; Zhang, Jiayou ; Ma, Xiao-Xia

Influenza A virus (IAV) poses a threat to patients receiving immunosuppressive medications since they are more susceptible to infection with severe symptoms, and even death. Understanding the direct effects of immunosuppressants on IAV infection is critical for optimizing immunosuppression in these patients who are infected or at risk of influenza virus infection. We profiled the effects of 10 immunosuppressants, explored the antiviral mechanisms of immunosuppressants, and demonstrated the combined effects of immunosuppressants with the antiviral drug oseltamivir in IAV-infected cell models. We found that mycophenolic acid (MPA) strongly inhibits viral RNA replication via depleting cellular guanosine pool. Treatment with 6-Thioguanine (6-TG) promoted viral protein degradation through a proteasomal pathway. Filgotinib blocked mRNA splicing of matrix protein 2, resulting in decreased viral particle assembly. Furthermore, combined treatment with immunosuppressants and oseltamivir inhibits IAV viral particle production in an additive or synergic manner. Our results suggest that MPA, 6-TG, and filgotinib could be the preferential choices for patients who must take immunosuppressants but are at risk of influenza virus infection.

31 Dec 2024·RENAL FAILURE

Serum antineutrophil cytoplasmic antibody positivity at the time of renal biopsy is associated with disease activity of lupus nephritis

Article

Author: Wan, Jianxin ; Chen, Yi ; Zhang, Jing ; Lian, Ruoshan

OBJECTIVE:

To investigate the correlations between serum antineutrophil cytoplasmic antibody (ANCA) and clinicopathological features, induction treatment response, and prognosis of lupus nephritis (LN) patients.

METHODS:

In this retrospective study, biopsy-proven LN patients from October 2010 to September 2020 were tested for serum ANCA by indirect immunofluorescence and ELISA and were divided into ANCA-positive group and ANCA-negative group. The clinicopathological data of the two groups were analyzed and compared.

RESULTS:

Thirty-five of 115 patients (30.43%) were seropositive for ANCA. ANCA-positive patients had significantly higher systemic lupus erythematosus activity index and activity index scores, higher 24-h urinary protein, and lower complement three levels (p = 0.001, 0.028, 0.023, 0.009, respectively). The incidences of oral ulcers, thrombocytopenia, and leukocyturia, and the positive rates of anti-dsDNA antibody and anti-histone antibody were significantly higher in ANCA-positive group (p = 0.006, 0.019, 0.012, 0.001, 0.019, respectively). Class IV LN and fibrinoid necrosis/karyorrhexis were significantly more common in the ANCA-positive group (p = 0.027, 0.002). There was no significant difference in the total remission rate of ANCA-positive patients receiving cyclophosphamide and mycophenolate mofetil as induction therapies (83.33% vs. 66.67%, p > 0.05), while patients receiving cyclophosphamide as induction therapy had a higher total remission rate than those receiving other immunosuppressants (83.33% vs. 20%, p = 0.028).

CONCLUSIONS:

LN patients with ANCA seropositivity at renal biopsy have a significantly higher disease activity, and their pathological manifestations are predominantly proliferative LN. These patients require a more active immunosuppressive therapy with cyclophosphamide or mycophenolate mofetil to improve their remission rate.

News (Medical) associated with Mycophenolate Mofetil

29 Oct 2024

·www.globenewswire.com

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal range; Third subject was recently transplanted and is on trajectory for insulin independence - Islet engraftment in the first two subjects with tegoprubart estimated three to five times higher than engraftment in three comparable subjects receiving standard of care tacrolimus-based immunosuppression - Treatment with tegoprubart was generally well tolerated - Study data to be presented by UChicago Medicine’s team in oral presentation at the 5th IPITA/HSCI/Breakthrough T1D Stem Cells Summit IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced positive data for the first three islet transplant recipients treated with an immunosuppression regimen that includes tegoprubart, the Company’s investigational anti-CD40L antibody, for prevention of islet transplant rejection in subjects with type 1 diabetes (T1D). The investigator-initiated trial, conducted by the research team at the University of Chicago Medicine’s Transplantation Institute, demonstrated potentially the first human cases of insulin independence achieved using an anti-CD40L monoclonal antibody therapy without the use of tacrolimus, the current standard of care for prevention of transplant rejection. The first two subjects achieved insulin independence and normal hemoglobin A1C (HbA1c) levels, a measure of average blood glucose, post-transplant. The third subject, who recently received an islet transplant, decreased insulin use by more than 60% three days following the procedure and continues on an insulin independence trajectory. Subjects on study received islet transplants combined with induction therapy, mycophenolate mofetil (MMF), and tegoprubart, given every third week by intravenous (IV) infusion. The first two subjects achieved insulin independence and presented stable islet graft function at approximately three months and six months post-transplant, respectively. Islet engraftment, measured by graft function standardized to the number of islets infused, was three to five times higher than three comparable subjects outside this study who received tacrolimus-based immunosuppression, suggesting treatment with tegoprubart is less toxic to transplanted islets resulting in improved graft survival and function. Treatment was generally well tolerated in all subjects with no unexpected adverse events or hypoglycemic episodes. After initial islet transplant, the first participant reduced insulin requirements by over 60% and normalized blood glucose control. The first patient then achieved insulin independence approximately two weeks after the second islet transplantation procedure. The data are being featured in an oral presentation at the International Pancreas and Islet Transplantation Association (IPITA), Harvard Stem Cell Institute (HSCI), and Breakthrough T1D (formerly JDRF) 5th Annual Summit on Stem Cell Derived Islets on Tuesday, October 29, 2024. “We are very pleased that tegoprubart played a pivotal role in yet another landmark advance in transplantation research through the work of Dr. Witkowski, Dr. Fung and their team at UChicago Medicine,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “Following promising results in kidney allotransplant procedures as well as heart and kidney xenograft procedures, these data from subjects following islet transplantation further demonstrate tegoprubart’s potential to protect transplanted organs and cells. Dr. Witkowski’s study also further reinforces prior study results showing that tegoprubart may offer a favorable safety and efficacy profile compared to tacrolimus-based immunosuppression regimens.” “These data are another step in our quest to achieve a path for functional cures in type 1 diabetes,” said Piotr Witkowski, M.D., Ph.D., Director, Pancreas and Islet Transplant Program, UChicago Medicine and one of the study’s lead investigators. “For more than 30 years, we have been looking for options that can deliver target levels of immunosuppression without the side effects associated with standard of care, including toxicity to the kidneys, central nervous system and islet cells, and increased risk of diabetes and hypertension. These data further support tegoprubart as a novel immunosuppression option that can play a central role in advancing islets transplantation as a potentially transformational alternative for subjects with type 1 diabetes.” “Breakthrough T1D is proud to fund and support this research and is encouraged by the tegoprubart study showing that subjects who received islet transplants with a tacrolimus-free immunosuppressive regimen are making insulin again,” said Breakthrough T1D Chief Scientific Officer Sanjoy Dutta, Ph.D. “Islet replacement therapies are a key priority for Breakthrough T1D, and we’re committed to driving research that moves us toward a world where these therapies are available to the broader T1D community. Achieving this goal requires novel approaches to keep transplanted cells functional with a tolerable immunosuppression regimen. These results are an important step toward that goal, and we look forward to seeing additional data.” Efficacy and Safety Results The first participant was a 42-year-old female with a baseline weight of 88 kg/194 lbs (BMI of 30). At 90 days post-transplant, the participant’s HbA1c level improved to 6.0% (from 8.4% at baseline) and daily insulin dose decreased to 16 units per day (from 80 units per day at baseline). After 16 weeks, the participant received a second islet transplant, and approximately two weeks later achieved insulin independence, maintaining improved HbA1c levels of 5.4% afterwards. The second participant was a 30-year-old female with a baseline weight of 50 kg/110 lbs (BMI of 21). This patient stopped insulin support (from 60 units per day at baseline) four weeks after the islet transplant. Her HbA1c levels improved to 5.8% and below (from 8.5% at baseline) starting at seven weeks after the transplant. The third participant was a 37-year-old male with a baseline weight of 92 kg/203 lbs (BMI of 30) with a baseline HbA1C of 9.3%. This patient was discharged home on day three post-transplant, requiring 29 units of insulin (from 90 units per day at baseline). The treatment was generally well tolerated in all subjects with no unexpected adverse events, severe hypoglycemic episodes, or graft rejection. In January 2024, Eledon announced that it would be supplying tegoprubart for this investigator-led clinical trial with the UChicago Medicine Transplantation Institute for pancreatic islet transplantation in subjects with type 1 diabetes (NCT06305286). Tegoprubart is the cornerstone component of the chronic immunosuppressive regimen for trial participants and is being evaluated for the prevention of transplant rejection in the trial. Funding for the study includes grants from Breakthrough T1D (formerly known as JDRF) and The Cure Alliance. About Islet Transplantation for Type 1 Diabetes Pancreatic islet transplantation is a minimally invasive procedure developed to provide blood glucose control for subjects with type 1 diabetes and minimize or eliminate dependence on insulin. During the procedure, pancreatic islets containing insulin-producing beta cells are isolated from the pancreas of a deceased organ donor and infused through a small catheter into the patient’s liver. The islet cells lodge in small blood vessels in the liver and release insulin. Post-procedure, subjects remain on immunosuppression therapy to prevent transplant rejection. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com. Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, expected or future results of tegoprubart trials and its ability to prevent rejection in connection with islet cell transplantation or kidney transplantation, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sites, as well as patient enrollment; and risks relating to costs of clinical trials and the sufficiency of the company’s capital resources to fund planned clinical trials. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Stephen JasperGilmartin Group(858) 525 2047stephen@gilmartinir.com Media Contact: Jenna UrbanBerry & Company Public Relations(212) 253 8881jurban@berrypr.com Source: Eledon Pharmaceuticals

Clinical ResultImmunotherapyClinical Study

29 Oct 2024

·endpts.com

Two type 1 diabetes patients are insulin-free after Eledon's immunosuppressant and an islet transplant

Eledon Pharmaceuticals’ experimental immunosuppressant helped two patients with type 1 diabetes go insulin-free following an islet cell transplant, the company announced Tuesday. The company’s stock $ELDN rose about 12% on Tuesday morning after Eledon announced the data and an $85 million offering . It said the investigator-initiated trial, which is being conducted by researchers at UChicago Medicine Transplant Institute, could have produced the first results showing that two patients became insulin-independent after undergoing treatment with an anti-CD40L monoclonal antibody and without taking tacrolimus, which is the current standard of care to prevent transplant rejections. Tacrolimus, a type of immunosuppressant, comes with a laundry list of toxicity issues, including kidney and beta cell toxicity, post-transplant new-onset diabetes, hypertension, brain fog and tremors, according to Eledon CEO David-Alexandre Gros. “We’re trying to get people off insulin, and yet, right when we’re giving them new islet cells, we’re giving them a drug that is going to harm,” Gros told Endpoints News . “We’re looking to develop a new generation of immunomodulator, one that will be both more effective as well as safer than the current standard of care.” Gros pointed to Vertex’s work in stem cell-derived islet cell therapy — the company announced over the summer that three of its patients had gone insulin-free using VX-880 — but patients also have to be on chronic immunosuppressive therapy. Vertex is working on VX-264, which is designed to treat patients without immunosuppressants, but Gros thinks there will be a place for Eledon’s drug, called tegoprubart, if VX-264 fails. “What we’re hoping to do is to unlock this market if tegoprubart can provide as good or better protection but without all of the side effects,” Gros said. “And so far, the data is very encouraging.” In the study, patients received islet transplants combined with induction therapy — mycophenolate mofetil plus tegoprubart — every three weeks by an IV infusion. The company said treatment with tegoprubart was “generally well-tolerated” in all subjects, with no unexpected adverse events, graft rejection or hypoglycemic episodes. A third patient decreased their insulin use by more than 60% three days after the transplant procedure. Along with achieving insulin independence at approximately three months and six months post-transplant, the first two patients also recorded normal HbA1c levels. All three patients saw improved islet engraftment — engraftment was three to five times higher than three comparable subjects who received only tacrolimus — and Eledon said this suggests that tegoprubart is “less toxic” to transplanted islets and led to improved graft survival and function. Back in 2020, Eledon bought tegoprubart through its acquisition of Anelixis, though the ALS Therapy Development Institute had discovered the drug. Eledon first ran a Phase 2 trial with the drug in ALS patients before pivoting to transplant rejection. It still has plans to develop the drug in ALS. The company is continuing the trial in islet cell transplant, which is designed for up to nine patients, and it has three ongoing trials in kidney transplantation. Editor’s note: This story has been updated with the name of the UChicago Medicine Transplant Institute.

Clinical ResultCell TherapyPhase 2AcquisitionImmunotherapy

27 Sep 2024

·www.biospace.com

Roche Looks to Push Gazyva Into Lupus Nephritis With Promising Late-Stage Data

iStock, JHVEPhoto In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the indication. Roche subsidiary Genentech announced on Thursday that Gazyva (obinutuzumab) met its primary efficacy endpoint in the Phase III REGENCY study of lupus nephritis. The pharma will present these data to the FDA and other global health authorities with the goal of securing approvals in this indication. Without revealing specific data, Roche in its announcement indicated that Gazyva treatment elicited “statistically significant and clinically meaningful treatment benefits” in patients with active lupus nephritis. At 76 weeks, more patients treated with Gazyva—given on top of standard therapy with mycophenolate mofetil and glucocorticoids—reached complete renal response (CRR) versus standard therapy alone. Roche CMO Levi Garraway in a statement called this CRR result “robust,” noting that it is “associated with long-term preservation of kidney function and delay or prevention of end-stage kidney disease.” Gazyva also aced two of its key secondary endpoints in REGENCY, including the proportion of patients hitting CRR alongside a successful reduction in corticosteroid use, as well as an improvement in proteinuric response. Both measures are important markers of disease control in lupus nephritis, according to the company. Roche said it will share REGENCY’s findings for presentation at an upcoming medical meeting and for publication in a peer-reviewed journal. Lupus nephritis is a kidney complication caused by the autoimmune disease systemic lupus erythematosus (SLE). In patients with lupus nephritis, B cells cause overactive and persistent inflammation, which damages the kidney and can cause end-stage kidney disease, typically within 10 years. At its most advanced stages, the kidney damage that lupus nephritis causes can only be treated through transplantation or dialysis. Gazyva is an intravenously administered monoclonal antibody that works by targeting the CD20 surface protein, which is commonly found on immature and mature lymphocytes. Once bound to its target, Gazyva can trigger cell death, ultimately leading to an overall decline in the levels of disease-causing B cells. This mechanism of action has won Gazyva several FDA approvals, including for chronic lymphocytic leukemia and follicular lymphoma. Roche is continuing to advance Gazyva into other B cell-mediated diseases, including membranous nephropathy, childhood-onset idiopathic nephrotic syndrome and SLE. Gazyva’s late-stage victory on Thursday continues the industry’s recent winning streak in the autoimmune space. Earlier this week, partners Biogen and UCB reported that their investigational therapy dapirolizumab pegol cleared the Phase III PHOENYCS GO study in SLE , demonstrating significant improvements in moderate-to-severe disease activity versus placebo. Last month, startup Navigator Medicines raked in $100 million in its Series A funding round , which it will use to develop its bispecific antibody NAV-240 for autoimmune conditions.

Phase 3Clinical ResultDrug ApprovalPhase 2Immunotherapy

100 Deals associated with Mycophenolate Mofetil

External Link

KEGG	Wiki	ATC	Drug Bank
D00752	Mycophenolate Mofetil	L04AA06	DB00688

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hematopoietic stem cell transplantation	JP	Chugai Pharmaceutical Co., Ltd.	25 Jun 2021
Lupus Nephritis	JP	Chugai Pharmaceutical Co., Ltd.	13 May 2016
Rejection of pancreas transplant	JP	Chugai Pharmaceutical Co., Ltd.	09 Feb 2005
Cardiac transplant rejection	JP	Chugai Pharmaceutical Co., Ltd.	31 Jan 2003
Liver transplant rejection	JP	Chugai Pharmaceutical Co., Ltd.	31 Jan 2003
Lung transplant rejection	JP	Chugai Pharmaceutical Co., Ltd.	31 Jan 2003
Renal transplant rejection	JP	Chugai Pharmaceutical Co., Ltd.	22 Dec 2000
Graft Rejection	US	Roche Palo Alto LLC	03 May 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
acute leukemia	Phase 3	US	National Cancer Institute	25 Jun 2019
acute leukemia	Phase 3	US	National Heart, Lung & Blood Institute	25 Jun 2019
Lymphoma	Phase 3	US	National Heart, Lung & Blood Institute	25 Jun 2019
Lymphoma	Phase 3	US	National Cancer Institute	25 Jun 2019
Myelodysplastic Syndromes	Phase 3	US	National Heart, Lung & Blood Institute	25 Jun 2019
Myelodysplastic Syndromes	Phase 3	US	National Cancer Institute	25 Jun 2019
Philadelphia chromosome positive chronic myelogenous leukemia	Phase 3	US	National Heart, Lung & Blood Institute	25 Jun 2019
Philadelphia chromosome positive chronic myelogenous leukemia	Phase 3	US	National Cancer Institute	25 Jun 2019
Uveitis	Phase 3	US	National Eye Institute	01 Aug 2013
Uveitis	Phase 3	AU	National Eye Institute	01 Aug 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02582775 (CTgov)	Phase 2	Epidermolysis Bullosa	17	Donor mesenchymal stem cell infusions+Fludarabine+Cyclophosphamide+Thymoglobulin+Tacrolimus+mycophenolate mofetil (RDEB: HCT Plus MSC Arm B)	fntibtycog(tkwzkdanma) = wugzgcgjnt jgirmbirem (eovtqofnjy, zqdahptxij - ikhsfuakyq) View more	-	19 Sep 2024
				Donor mesenchymal stem cell infusions+Fludarabine+Cyclophosphamide+Thymoglobulin+Tacrolimus+mycophenolate mofetil (RDEB: HCT Plus MSC Arm E)	fntibtycog(tkwzkdanma) = gjorlzwabx jgirmbirem (eovtqofnjy, mcyjqhyzum - xwgpeebtff) View more
NCT03480360 (CTgov)	Phase 3	Acute Myeloid Leukemia \| Chronic phase chronic myeloid leukemia \| Chronic Lymphocytic Leukemia ... View more	21	G-CSF+Fludarabine+cyclophosphamide+Tacrolimus+cellcept	uvpegxpamj(wpgnmqikvp) = iykcojjxtk uclpeobpaa (bfjebutvvh, jmxqvvebji - hqiptfvjaj) View more	-	23 Jul 2024
EULAR2024	Not Applicable	Add-on anti-topoisomerase 1 antibody	5	Mycophenolate mofetil (MMF)	eqqjjthcoj(gbvjahrkvx) = one patient developed anaphylaxis during the first infusion ebahqnhlqf (drlenolhaz )	Positive	05 Jun 2024
				Rituximab (RTX)
FDA_CDER Manual	Not Applicable	Liver transplant rejection	565	MYCOPHENOLATE MOFETIL	pimpkmkfsf(brzbiidkxg) = irvmxrtxps mhfmmoziya (opubmnlwjh ) View more	Positive	01 May 2024
FDA_CDER Manual	Not Applicable	Renal transplant rejection	491	MYCOPHENOLATE MOFETIL 2 g/day (Europe Study)	atrdpttcgd(dprfaseaag) = mhddzkiaio yhzyscpmrv (xqnjcysqlg ) View more	Positive	01 May 2024
				MYCOPHENOLATE MOFETIL 3 g/day (Europe Study)	atrdpttcgd(dprfaseaag) = yeuqdyuzbp yhzyscpmrv (xqnjcysqlg ) View more
FDA_CDER Manual	Not Applicable	Cardiac transplant rejection	650	MYCOPHENOLATE MOFETIL (ITT)	miltfiijke(uhkmjvdxhk) = nyozwhihih vfkegxksna (zbuufmnaiv ) View more	Positive	01 May 2024
				MYCOPHENOLATE MOFETIL (Treated Patients)	miltfiijke(uhkmjvdxhk) = zqsahhqxeb vfkegxksna (zbuufmnaiv ) View more
FDA_CDER Manual	Not Applicable	Renal transplant rejection	503	Mycophenolate Mofetil 2g/day (Europe/Canada/ Australia Study)	dhviwyqaev(tebbybnnvh) = ehbleqltll hhfofkwmxu (inxaecmbqb ) View more	Positive	01 May 2024
				Mycophenolate Mofetil 3g/day (Europe/Canada/ Australia Study)	dhviwyqaev(tebbybnnvh) = oemqgtuswh hhfofkwmxu (inxaecmbqb ) View more
FDA_CDER Manual	Not Applicable	Renal transplant rejection	499	Mycophenolate Mofetil 2g/day (USA Study)	cbkzpaequg(kmcrrqxrwi) = aipqmxzbem jerzfsbcjl (mkoncdvhwj ) View more	Positive	01 May 2024
				Mycophenolate Mofetil 3g/day (USA Study)	cbkzpaequg(kmcrrqxrwi) = fbiecumpwx jerzfsbcjl (mkoncdvhwj ) View more
ISN WCN2024	Not Applicable	Renal transplant rejection plasma concentrations of mycophenolic acid (MPA)	11	Mycophenolic mofetil (MMF)	njfkzovdxu(pupyenaemb) = tpwmiqknfn klivwdjimj (anjjyhpftq, 1.02)	Negative	01 Apr 2024
NCT02251821 (CTgov)	Phase 2	Primary Myelofibrosis	61	Umbilical Cord Blood Transplantation+Fludarabine Phosphate+Busulfan+cyclophosphamide+Melphalan+Tacrolimus+Ruxolitinib+Mycophenolate Mofetil+Methotrexate	cqrklpuzjb(bnzlaltcuw) = bfycttlflj hhjnebsgns (ywtogcdkvk, hqbnwhwyvd - oxmomqjeti) View more	-	05 Mar 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis